SCLC Clinical Trials
Here are the 6 most popular medical studies for sclc
Alkylating agents
CLAMP for Small Cell Lung Cancer
This trial is testing whether adding mycophenolate mofetil and allopurinol to chemotherapy drugs used for relapsed small cell lung cancer will improve outcomes compared to using other single agent chemotherapy drugs.
PD-1/PD-L1 Inhibitor
Pembrolizumab + Investigational Agents for Small Cell Lung Cancer
This trial will study the safety and efficacy of pembrolizumab in combination with investigational agents in people with anti-PD-1/PD-L1 refractory ES-SCLC who need second-line treatment. The trial will have two parts: a safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D), and an efficacy evaluation.
Popular filter options for sclc trials
NSCLC Clinical Trials
View 72 NSCLC medical studies.
Monoclonal Antibodies
SGN-CEACAM5C for Stomach Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.
Enzyme Depletion
ADI-PEG 20 + Gemcitabine + Docetaxel for Lung Cancer
This trial tests a 3-drug combo to treat lung cancer that has progressed on frontline treatment; first, a phase I will test different doses, then phase II will use the recommended dose to assess efficacy.
Non-Small Cell Lung Cancer Clinical Trials
View 63 Non-Small Cell Lung Cancer medical studies.
Monoclonal Antibodies
SGN-CEACAM5C for Stomach Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.
Enzyme Depletion
ADI-PEG 20 + Gemcitabine + Docetaxel for Lung Cancer
This trial tests a 3-drug combo to treat lung cancer that has progressed on frontline treatment; first, a phase I will test different doses, then phase II will use the recommended dose to assess efficacy.
Metastatic Small Cell Lung Cancer Clinical Trials
View 95 metastatic small cell lung cancer medical studies.
Monoclonal Antibodies
SGN-CEACAM5C for Stomach Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.
EGFR Positive Clinical Trials
View 19 EGFR positive medical studies.
Enzyme Depletion
ADI-PEG 20 + Gemcitabine + Docetaxel for Lung Cancer
This trial tests a 3-drug combo to treat lung cancer that has progressed on frontline treatment; first, a phase I will test different doses, then phase II will use the recommended dose to assess efficacy.
Small Molecule Kinase Inhibitor
Lazertinib + Subcutaneous Amivantamab vs. Intravenous Amivantamab for Non-Small Cell Lung Cancer
This trial is testing a new, easier to use formulation of amivantamab, which has the potential to reduce administration time and improve the patient and physician experience.
ALK Positive Clinical Trials
View 16 ALK positive medical studies.
Enzyme Depletion
ADI-PEG 20 + Gemcitabine + Docetaxel for Lung Cancer
This trial tests a 3-drug combo to treat lung cancer that has progressed on frontline treatment; first, a phase I will test different doses, then phase II will use the recommended dose to assess efficacy.
Monoclonal Antibodies
Pembrolizumab + Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer
This trial is testing whether adding the drug pembrolizumab to the standard treatment of carboplatin and pemetrexed will help patients with EGFR-mutation-positive NSCLC who have progressed on targeted therapies.
Phase 3 Small Cell Lung Cancer Clinical Trials
View 95 phase 3 small cell lung cancer medical studies.
Checkpoint Inhibitor
Immunotherapy + Chemotherapy for Small Cell Lung Cancer
This trial will compare two immunotherapy treatments for small cell lung cancer. The first treatment is a combination of pembrolizumab/vibostolimab with chemotherapy. The second treatment is a combination of atezolizumab with chemotherapy. The study will measure overall survival rates to see if the first treatment is superior to the second.
Small Molecule Kinase Inhibitor
Lazertinib + Subcutaneous Amivantamab vs. Intravenous Amivantamab for Non-Small Cell Lung Cancer
This trial is testing a new, easier to use formulation of amivantamab, which has the potential to reduce administration time and improve the patient and physician experience.
Immunostimulant
Combination Immunotherapy for Lung Cancer
This trial is testing immunotherapy treatment with N-803 and pembrolizumab for advanced non-small cell lung cancer. N-803 may activate natural killer cells so that they can stimulate an immune response to help fight cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Monoclonal Antibodies
Pembrolizumab + Platinum Doublet Chemotherapy for Non-Small Cell Lung Cancer
This trial will see if a new cancer treatment is better than current treatments. The new treatment is pembrolizumab (MK-3475) given before and after surgery for people with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC).
Small Cell Lung Cancer Clinical Trials With No Placebo
View 95 small cell lung cancer medical studies that do not have a placebo group.
Monoclonal Antibodies
SGN-CEACAM5C for Stomach Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.
Monoclonal Antibodies
BI 764532 for Small Cell Lung Cancer
This trial is for adults with advanced small-cell lung cancer & neuroendocrine tumours. It tests 2 doses of BI 764532, an antibody-like molecule, to see if it shrinks tumours & is safe & tolerable. Participants visit the study site regularly to monitor safety & record effects.
Enzyme Depletion
ADI-PEG 20 + Gemcitabine + Docetaxel for Lung Cancer
This trial tests a 3-drug combo to treat lung cancer that has progressed on frontline treatment; first, a phase I will test different doses, then phase II will use the recommended dose to assess efficacy.
View More Sclc Trials
See another 68 many medical studies focused on sclc.
Frequently Asked Questions
Introduction to sclc
What are the top hospitals conducting sclc research?
When it comes to cutting-edge clinical trials in the realm of small cell lung cancer (SCLC), several top hospitals are leading the charge. Memorial Sloan Kettering Cancer Center, located in New York City, is at the forefront with seven active SCLC trials and a total of 23 completed trials dedicated to this aggressive form of lung cancer. Since their first recorded trial in 2007, they have been committed to pushing boundaries and seeking innovative treatment options for patients. Washington University School of Medicine in Saint Louis also deserves recognition, boasting six ongoing SCLC trials and an impressive record of 24 previous trials dating back to their inaugural study in 1992.
Meanwhile, down south at Moffitt Cancer Center in Tampa, researchers are making significant strides as well. With six active SCLC trials and 18 past studies under their belt since initiating their first trial on this condition back in 2008, they demonstrate dedication towards improving patient outcomes. PCR Oncology based in Arroyo Grande may be smaller-scale comparatively but plays a vital role with six current SCLC clinical trials; although they have only conducted five all-time investigations since recording its maiden trial on sclc cases In2007 proving every effort made towards understanding this disease is valuable.
Lastly yet importantly,the Lewis Cancer and Research Pavilion at Saint Joseph's/Candler situatedin Savannah seeks contribution through conducting six ongoing tests which adds over previous nine held experiments tracingback ten years ago till when it started participating from year2008 into such widespread medical research.The efforts by these top hospitals indicate not only progress but hope for those affected by small cell lung cancer worldwide.Through each trial conducted we edge closer toward unravelling mysteries surrounding treatments which ensure brighter future for countless patients suffering from this deadly condition
Which are the best cities for sclc clinical trials?
When it comes to small cell lung cancer (SCLC) clinical trials, several cities stand out as key players in research and development. Anchorage, Alaska leads the pack with 28 active trials focusing on promising treatments such as Pembrolizumab, Erlotinib Hydrochloride, and Cisplatin. Following closely behind is Los Angeles, California, Alaska leads the pack with 28 active trials focusing on promising treatments such as Pembrolizumab, Erlotinib Hydrochloride, and Cisplatin. Following closely behind is Los Angeles, California with 27 ongoing studies investigating similar interventions like Pembrolizumab and Erlotinib Hydrochloride. Houston, Texas also plays a significant role in SCLC research with 25 active trials exploring innovative approaches such as Local Consolidation Therapy and the NovoTTF-200M device. These cities offer individuals diagnosed with SCLC access to cutting-edge clinical trials that may pave the way for improved treatment options and outcomes.
Which are the top treatments for sclc being explored in clinical trials?
In the realm of small cell lung cancer (SCLC) research, several treatments are currently under investigation in clinical trials. Leading the pack is pembrolizumab, a formidable contender with 10 ongoing trials and a history of 26 all-time SCLC trials since its debut in 2014. Another noteworthy player is durvalumab, making waves with three active trials and an impressive track record of 33 all-time SCLC trials since its introduction in 2016. Additionally, stereotactic radiosurgery has emerged as a newcomer on the scene, showing promise with two active trials and three total SCLC trials recorded since its first listing in 2020. As researchers delve deeper into these potential breakthroughs, new avenues for treating SCLC continue to emerge on the horizon.
What are the most recent clinical trials for sclc?
Promising advancements in the field of small cell lung cancer (SCLC) treatment have emerged through recent clinical trials. One notable trial investigates the efficacy of cemiplimab, a novel therapeutic approach for SCLC patients. This Phase 2 study offers hope for improved outcomes and enhanced quality of life. Additionally, ongoing research focuses on dose-finding strategies in non-small cell lung cancer (NSCLC), aiming to adapt them to benefit individuals with SCLC as well. Furthermore, DB-1311 has shown potential as a treatment option through its dual-phase investigation encompassing both Phase 1 and Phase 2 trials. Another experimentall lung cancer (NSCLC), aiming to adapt them to benefit individuals with SCLC as well. Furthermore, DB-1311 has shown potential as a treatment option through its dual-phase investigation encompassing both Phase 1 and Phase 2 trials. Another experimental drug, LB2102, is currently being evaluated in a Phase 1 trial for its effectiveness against SCLC. Tocilizumab also presents promise as it undergoes combined Phase 1 and Phase 2 testing towards developing innovative treatment options for this aggressive form of lung cancer. These groundbreaking studies mark significant steps forward in the fight against SCLC and offer renewed optimism to those affected by this disease.
What sclc clinical trials were recently completed?
Several notable clinical trials evaluating treatments for small cell lung cancer (SCLC) have recently concluded, offering valuable insights into potential therapeutic options. In July 2021, BeiGene's trial investigating the effectiveness of Ociperlimab concluded successfully. Another significant trial was completed in March 2021 by EMD Serono Research & Development Institute, Inc., examining the efficacy of Berzosertib. These recent advancements contribute to our understanding and bring hope to patients battling SCLC.